New partnerships announced for the World Stem Cells & Regenerative Medicine Congress 2013
As the regenerative medicine industry grows from strength to strength, the right strategic partnerships formed in the coming years will certainly influence the level of success in this space. Cell therapy developers need to attract the right partners and investors to drive forward their stem-cell based innovations, while the services & bioprocessing sector has a great responsibility (and opportunity) to bring forward some disruptive innovations that will enable efficient scale up and automated manufacture. The route towards large scale commercialisation of cell therapies is barely trodden so harnessing external expertise and interacting in this collegiate industry is essential for all organisations. There is certainly a feeling that one companies success will subsequently have a positive impact on the industry at large given the inevitable media and investor interest, particularly in light of the life changing promise cell therapies offer patients with severe unmet medical need.
For the past 7 years, the World Stem Cells & Regenerative Medicine Congress has grown to become one of the leading global marketplaces, networking events and idea sharing conferences for the stem cell & regenerative medicine industry to establish and maintain their strategic relationships. Following the success of previous years, the 2013 congress is already growing to welcome partners, both new and old. This week it is a pleasure to announce that EMD Millipore have continued to be strongly involved with the event and that MaSTherCell will be exhibiting at the 2013 congress. More on these two companies (along with the remaining event sponsors) in future blogs.
If you are interested in using the 2013 World Stem Cells & Regenerative Medicine Congress to meet your future business objectives, have a read of the Event Prospectus. You can also take a look at the existing 2013 partners here.
For more updates on pharma, biotech and R&D, follow us on Twitter: @biopharmaevents or join our LinkedIn group: BioPharma- Networking for Pharmaceuticals, Biotech and R&D
at 5:07 am
GBI Research analysis finds that stem cell therapies have immense market potential driven by strong pipeline that caters to high unmet needs. Increasing investment and supportive regulatory environment in key geographies will help the stem cells industry to realize its full potential. Stem cell therapies high market potential is based on their unique ability to offer curative treatment in comparison to the symptomatic treatment offered by conventional treatments.
Strategic partnerships between Pharmaceutical companies and Stem cell research companies are boosting stem cell research and development. Almost 90% of the drugs in clinical trials fail due to factors such as lack of effectiveness and adverse side effects of the drug. Usually animal or tumor cells are being used and this leads to jury-rigged tests. Hence all major pharmaceutical companies are looking forward for new technologies that increase the possibility to launch new therapies in the market place.
At present, there has been a spur in investments from pharmaceutical companies into stem cell research through strategic partnerships with stem cell research companies. Major pharmaceutical companies have planned and aligned their objectives to enter the stem cell market in the next 3-5 years, with a few strategic partnerships already formed between pharmaceutical companies and stem cell research based companies. Pharmaceutical companies are also exploring various methods where stem cells could be utilized in drug discovery process to accelerate the discovery of novel drug molecules.
GBI Research, the leading business intelligence provider, has released its latest research “Stem Cell Research Market to 2017- Strong Pipeline, High Unmet Needs in Chronic Diseases and Favorable Government Policies to Boost Stem Cell R&D”. The report provides an in-depth analysis on global stem cell research and development. The report suggests investment decisions in stem cell research by providing trends and information on pipelines, federal spending, venture capitalist perspective, country regulations, competitive landscape and market potential. It also provides an analysis on the current investments in various stem cell research segments. In addition to this, the report covers market drivers and challenges for stem cell research and development market.